News | December 05, 2025
Lupin inks US licensing deal with Valorum for biosimilar Armlupeg
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Subscribe To Our Newsletter & Stay Updated
